Actuate Therapeutics, Inc. SEC filings ACTU
Actuate Therapeutics, Inc. has 192 filings in SEC EDGAR's recent list, going back to Oct 8, 2015. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 30, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 28, 2026 | Oct 26, 2026 |
| 424B5 | Prospectus supplement | Oct 28, 2026 | — |
| EFFECT | Filing | Oct 26, 2026 | — |
| S-1/A | Amended registration statement | Oct 19, 2026 | — |
| S-1/A | Amended registration statement | Oct 14, 2026 | — |
| FWP | Free writing prospectus | Oct 8, 2026 | — |
| S-1 | Registration statement | Oct 6, 2026 | — |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 17, 2026 | Jul 15, 2026 |
| DRS | Filing | Jun 8, 2026 | — |
| 8-K |
Current report
Shareholder vote results
|
May 22, 2026 | May 21, 2026 |
| S-8 | Employee stock plan registration | May 14, 2026 | — |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
May 11, 2026 | May 11, 2026 |
| DEFA14A | Additional proxy material | May 6, 2026 | — |
| 8-K |
Current report
Officer or director change, Other events
|
May 6, 2026 | May 1, 2026 |
| ARS | Annual report to shareholders | Apr 9, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 6, 2026 | — |
| DEF 14A | Proxy statement | Apr 6, 2026 | May 21, 2026 |
| 10-K | Annual report | Mar 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Material agreement
|
Nov 28, 2025 | Nov 28, 2025 |
| 424B5 | Prospectus supplement | Nov 28, 2025 | — |
| 8-K |
Current report
Other events
|
Nov 21, 2025 | Nov 21, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 10, 2025 | Sep 10, 2025 |
| 424B5 | Prospectus supplement | Sep 10, 2025 | — |
| 424B5 | Prospectus supplement | Sep 9, 2025 | — |
| EFFECT | Filing | Sep 8, 2025 | — |
| CORRESP | Letter to the SEC | Sep 4, 2025 | — |
| CORRESP | Letter to the SEC | Sep 2, 2025 | — |
| S-3 | Shelf registration | Sep 2, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2025 | — |
| DRS | Filing | Aug 18, 2025 | — |
| 10-Q | Quarterly report | Aug 14, 2025 | Jun 30, 2025 |
| EFFECT | Filing | Aug 4, 2025 | — |
| 424B3 | Prospectus | Aug 4, 2025 | — |
| CORRESP | Letter to the SEC | Jul 31, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 31, 2025 | — |
| S-1 | Registration statement | Jul 25, 2025 | — |
| D | Filing | Jul 7, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 26, 2025 | Jun 25, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 5, 2025 | May 31, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 2, 2025 | May 31, 2025 |
| 8-K |
Current report
Shareholder vote results
|
May 23, 2025 | May 22, 2025 |
| S-8 | Employee stock plan registration | May 15, 2025 | — |
| 10-Q | Quarterly report | May 15, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Other events
|
May 6, 2025 | May 6, 2025 |
| EFFECT | Filing | Apr 16, 2025 | — |
| 424B3 | Prospectus | Apr 16, 2025 | — |
| CORRESP | Letter to the SEC | Apr 14, 2025 | — |
| D | Filing | Apr 10, 2025 | — |
| DEFA14A | Additional proxy material | Apr 9, 2025 | — |
| DEF 14A | Proxy statement | Apr 8, 2025 | May 22, 2025 |
| UPLOAD | Letter from the SEC | Apr 1, 2025 | — |
| S-1 | Registration statement | Mar 28, 2025 | — |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Mar 28, 2025 | Mar 27, 2025 |
| 10-K | Annual report | Mar 13, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Other events
|
Feb 7, 2025 | Feb 7, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 17, 2024 | Dec 17, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 12, 2024 | Nov 12, 2024 |
| 10-Q | Quarterly report | Sep 24, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Auditor change
|
Aug 19, 2024 | Aug 19, 2024 |
| S-8 | Employee stock plan registration | Aug 14, 2024 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Aug 14, 2024 | Aug 14, 2024 |
| SEC STAFF LETTER | Filing | Aug 13, 2024 | — |
| POS EX | Filing | Aug 13, 2024 | — |
| 424B4 | Prospectus | Aug 13, 2024 | — |
| EFFECT | Filing | Aug 12, 2024 | — |
| CERT | Filing | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 12, 2024 | — |
| 8-A12B/A | Form 8-a12b/a | Aug 12, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Aug 2, 2024 | — |
| CORRESP | Letter to the SEC | Jul 30, 2024 | — |
| CORRESP | Letter to the SEC | Jul 30, 2024 | — |
| CORRESP | Letter to the SEC | Jul 26, 2024 | — |
| CORRESP | Letter to the SEC | Jul 26, 2024 | — |
| FWP | Free writing prospectus | Jul 23, 2024 | — |
| S-1/A | Amended registration statement | Jul 23, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jul 19, 2024 | — |
| FWP | Free writing prospectus | Jul 19, 2024 | — |
| S-1/A | Amended registration statement | Jul 19, 2024 | — |
| CORRESP | Letter to the SEC | Jul 17, 2024 | — |
| CORRESP | Letter to the SEC | Jul 17, 2024 | — |
| S-1/A | Amended registration statement | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 15, 2024 | — |
| FWP | Free writing prospectus | Jun 21, 2024 | — |
| CORRESP | Letter to the SEC | Jun 21, 2024 | — |
| S-1/A | Amended registration statement | Jun 21, 2024 | — |
| 8-A12B | Filing | Jun 20, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 18, 2024 | — |
| FWP | Free writing prospectus | Jun 11, 2024 | — |
| S-1/A | Amended registration statement | Jun 11, 2024 | — |
| CORRESP | Letter to the SEC | Jun 11, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 24, 2024 | — |
| S-1 | Registration statement | May 24, 2024 | — |
| UPLOAD | Letter from the SEC | May 20, 2024 | — |
| DRS/A | Filing | May 13, 2024 | — |
| DRSLTR | Filing | May 10, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| DRSLTR | Filing | Apr 30, 2024 | — |
| DRS/A | Filing | Apr 30, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 19, 2024 | — |
| DRSLTR | Filing | Apr 9, 2024 | — |
| DRS/A | Filing | Apr 9, 2024 | — |
| SEC STAFF LETTER | Filing | Apr 3, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 1, 2024 | — |
| D | Filing | Mar 6, 2024 | — |
| DRSLTR | Filing | Mar 4, 2024 | — |
| DRS | Filing | Mar 4, 2024 | — |
| D/A | Filing | Dec 15, 2022 | — |
| D | Filing | Oct 19, 2022 | — |
| D | Filing | Dec 10, 2020 | — |
| D/A | Filing | Nov 14, 2019 | — |
| D | Filing | Oct 15, 2019 | — |
| D | Filing | May 13, 2019 | — |
| D | Filing | Sep 12, 2018 | — |
| D | Filing | Mar 20, 2017 | — |
| D | Filing | Feb 3, 2017 | — |
| D | Filing | Oct 8, 2015 | — |
Showing 127 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ACTU (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Fort Worth, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1652935
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.